Navigation Links
Janssen Announces Data from Simeprevir in Hepatitis C Patients Will Be Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
Date:4/8/2013

CORK, Ireland, April 8, 2013 /PRNewswire/ -- Janssen R&D Ireland (Janssen) announces that data will be presented on the investigational protease inhibitor simeprevir (TMC435) for the treatment of hepatitis C at The International Liver Congress 2013 of the European Association for the Study of the Liver (EASL), which will take place April 24 to 28 in Amsterdam, The Netherlands. These data presentations will include primary efficacy and safety results from the Phase 3 QUEST-1 study of simeprevir administered once daily in combination with pegylated interferon and ribavirin in treatment-naive genotype 1 chronic hepatitis C patients.

"The presentation of this primary efficacy Phase 3 data in a peer-reviewed setting such as The International Liver Congress represents a significant milestone for simeprevir," said Maria Beumont , M.D., medical leader for simeprevir, Janssen. "These data show the potential utility of simeprevir for people living with hepatitis C."

Janssen recently announced the submission of new drug applications in Japan and the United States for simeprevir administered once daily in combination with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients and anticipates submitting simeprevir for regulatory authorization in the EU in the first half of 2013. Simeprevir is also being studied in combination with pegylated interferon and ribavirin for the treatment of genotype 4 HCV infection and in several interferon-free regimens using selected combinations of direct-acting antiviral agents with different mechanisms of action.

Additional simeprevir data from the QUEST-2 study have been accepted by The International Liver Congress, but are subject to EASL's embargo policy until April 23. The data to be presented at The International Liver Congre
'/>"/>

SOURCE Janssen R&D Ireland
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
2. Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech
3. Charlie Wilson Teams Up With Janssen Biotech to Launch Making Awareness a Priority (M.A.P.)
4. Janssen Submits Additional Marketing Applications for ZYTIGA® in the U.S. and European Union
5. Dr. Victor Ambros and Dr. Gary Ruvkun Win 2012 Dr. Paul Janssen Award for Biomedical Research for Discovery of MicroRNAs
6. Janssen Research & Development, LLC, Sponsors First of its Kind Research Initiative to Advance Multiple Sclerosis Science
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
9. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
10. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
11. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... TORONTO , May 21, 2015 /PRNewswire/ - SQI ... SQIDF),a life sciences company that develops and commercializes proprietary ... its financial and operational results for the second fiscal ... the quarter the Company continued to advance business with ... Andrew Morris , President and CEO of SQI. ...
(Date:5/21/2015)... CA (PRWEB) May 21, 2015 ... has announced a partnership with PicnicHealth, a healthcare ... patients. Participants diagnosed with Inflammatory Bowel Disease (IBD) ... as a complementary uBiome research kit. Both companies ... , For more information on ...
(Date:5/21/2015)... May 21, 2015  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced positive updated results ... aldoxorubicin for the treatment of unresectable glioblastoma multiforme ... open-label, multisite trial is designed to investigate the ... whose tumors have progressed following prior treatment with ...
(Date:5/21/2015)... 2015 Tunnell Consulting, Inc. ... as senior statistician and Principal, a position to which ... the management and analysis of complex and large data ... , “We’re delighted to have Julia join the Tunnell ... said Dr. Philippe Cini, Group Vice President and leader ...
Breaking Biology Technology:SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2
... , , MINNEAPOLIS, Aug. 4 Techne ... has decided to pay a dividend of $0.25 per share for the ... August 31, 2009 to all common shareholders of record on August 17, ... Directors on a quarterly basis. , , Techne Corporation ...
... CRANBURY, N.J., Aug. 4 Palatin Technologies, Inc. (NYSE Amex: ... a Notice of Allowance from the U.S. Patent and Trademark ... Natriuretic Peptide Constructs." Allowed claims cover a family of ... including PL-3994, Palatin,s lead heart failure drug candidate. Palatin expects ...
... BEIJING, Aug. 4 /PRNewswire-Asia/ -- Sinovac Biotech Ltd.,(NYSE AMEX: ... China, announced today,that the clinical trial of its A/H1N1 influenza ... shot of the vaccine and, during the,three day observation period, ... and reliable in humans. , The ...
Cached Biology Technology:Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate 2Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate 3Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials 2Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials 3
(Date:4/27/2015)... April 27, 2015  For more than four decades, ... has been the premier worldwide event for the unmanned ... a must-attend event for any local, national, or trade ... emerging commercial markets and current applications of unmanned technologies. ... this projected $48 billion industry, and how it will ...
(Date:4/27/2015)... , Apr. 27, 2015 Profile Solutions, ... control and security systems is pleased to announce that ... as a consultant and member of its scientific advisory ... widely known as a thought leader in technology-enhanced learning ... Technology Group, and has published studies and books focused ...
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial ... Valley to implant a new miniaturized, wireless monitoring sensor ... is the first and only FDA-approved heart failure monitoring ... admissions when used by physicians to manage heart failure. ... that is implanted in the pulmonary artery (PA) during ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... cystic fibrosis (CF) patients with targeted treatment in ... French clinical trial published today in BMC Medicine ... with a rare genetic stop mutation responded positively ... Sermet-Gaudelus of Faculté de Médicine Necker in Paris ...
... with puzzles or chess, the reason may be in your ... geneticists at Washington University School of Medicine in St. Louis, ... gene that activates signaling pathways in the brain influences one ... gene, CHRM2, and performance IQ, which involves a person's ability ...
... that employs RNA, a tiny chemical cousin of DNA, to ... which nudging a gene awake would help alleviate disease, researchers ... method, which is being developed by UT Southwestern scientists, also ... the role that genes play in human health. ...
Cached Biology News:Genes and genius: Researchers confirm association between gene and intelligence 2Genes and genius: Researchers confirm association between gene and intelligence 3Novel laboratory technique nudges genes into activity 2Novel laboratory technique nudges genes into activity 3
...
Highly efficient electroporation solution suitable for transfection of plasmid DNA, oligonucleotides and siRNA. Compatible with all common electroporators....
Removes polysaccharide and phenolic inhibitors of PCR; yields DNA greater than 50 kb in length...
...
Biology Products: